clinimacs electroporation buffer (Miltenyi Biotec)
93
Structured Review
Miltenyi Biotec
clinimacs electroporation buffer

Clinimacs Electroporation Buffer, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/electroporation+buffer/CliniMACS+Electroporation+Buffer/pmc09986454-100-6-10
Average 93 stars, based on 4 article reviews

Clinimacs Electroporation Buffer, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/electroporation+buffer/CliniMACS+Electroporation+Buffer/pmc09986454-100-6-10
Average 93 stars, based on 4 article reviews
clinimacs electroporation buffer - by Bioz Stars,
2026-11
93/100 stars
Images
1) Product Images from "T-CAST: An optimized CAST-Seq pipeline for TALEN confirms superior safety and efficacy of obligate-heterodimeric scaffolds"
Article Title: T-CAST: An optimized CAST-Seq pipeline for TALEN confirms superior safety and efficacy of obligate-heterodimeric scaffolds
Journal: Frontiers in Genome Editing
doi: 10.3389/fgeed.2023.1130736
Figure Legend Snippet: Obligate-heterodimerization mitigates off-target activity of CCR5 -TALEN (A) Schematic of possible TALEN pairing combinations. Combinations are displayed for TALENs with wild-type (WT) and obligate-heterodimeric (OH) FokI domains. (B) Genotyping. Results of T7E1 assay of WT-TALEN and OH-TALEN (KKR-ELD and KVR-EAD configuration) are shown. 32°C indicates that T cells were subjected to transient cold-shock after electroporation, while control cells were constantly cultured at 37°C. * and ** specify p -values of <0.05 or <0.01 (Student’s t-test, n = 3–5). (C) TALEN expression. Percentage of TALEN-expressing T cells upon mRNA transfer as determined by flow cytometry (n = 1). (D,E) Structural variations. Circos plots illustrate T-CAST results with enlargement of the chromosome three region encompassing CCR5 and CCR2 loci. Lines represent chromosomal rearrangements with the CCR5 target site: OMTs with >20 hits in red, ambiguous classification (OMT/HMT) in yellow. (F,G) Genotyping. NGS at denoted sites was performed on untreated (UT) T cells, and T cells edited with WT-TALENs or OH-TALENs as indicated. The group in which the samples were originally identified is indicated on the bottom. *** specifies p -value<0.001 (Fisher’s exact test, Bonferroni corrected p -values).
Techniques Used: Activity Assay, TALENs, Electroporation, Control, Cell Culture, Expressing, Flow Cytometry
Figure Legend Snippet: T-CAST analysis for TRAC -targeting TALENs (A) Genotyping. Results of T7E1 assay of WT-TALEN and OH-TALEN (KKR-ELD and KVR-EAD configuration) are shown. 32°C indicates that T cells were subjected to transient cold-shock after electroporation, while control cells were constantly cultured at 37°C. * specifies p -value<0.05 (Student’s t-test, n = 3–6). (B) TCR expression. Displayed is the fraction of TCRα/β-negative T cells upon transfer of TALEN-encoding mRNA as determined by flow cytometry. Where indicated (32°C) T cells were subjected to a transient cold-shock. *** specifies p -value<0.001 (Student’s t-test; n = 3–7). (C–E) Structural variations. Circos plots illustrate T-CAST results with enlargement of the chromosome 14 region encompassing TRAC . Red lines represent chromosomal rearrangements (OMTs with >20 hits) with the TRAC target site. (F) Genotyping. NGS at denoted sites was performed on untreated (UT) T cells, and T cells edited with WT-TALENs or OH-TALENs as indicated. The group in which the samples were originally identified is indicated on the bottom. *** specifies p -value<0.001 (Fisher’s exact test, Bonferroni corrected p -values).
Techniques Used: TALENs, Electroporation, Control, Cell Culture, Expressing, Flow Cytometry
Related Articles
other:Article Title: Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene Article Snippet: At the 96 hour time point, residual unedited CD3+ T cells were removed from the TRC electroporated group by magnetic depletion using LD columns, CliniMACS buffer, and CD3 Microbeads (Miltenyi). Electroporation:Article Title: Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer Article Snippet: .. Thereafter, 1 × 10 6 OV-90 cells were mixed in 40 μL Article Title: Methods of performing GUIDE-Seq on primary human T cells Article Snippet: In a particular example, gene editing reagents can be delivered to a cell using a Nucleofector/Nucleofection® electroporation based delivery system (Lonza®). .. Other electroporation systems include, but are not limited to, MaxCyte electroporation systems, Article Title: Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer. Article Snippet: Treatment options for ovarian cancer patients are limited, and a high unmet clinical need remains for targeted and long-lasting, efficient drugs.. Genetically modified T cells expressing chimeric antigen receptors (CAR), are promising new drugs that can be directed towards a defined target and have shown efficient, as well as persisting, anti-tumor responses in many patients.. We sought to develop novel CAR T cells targeting ovarian cancer and to assess these candidates preclinically. Article Title: Identification and Characterization of Fully Human FOLR1-Targeting CAR T Cells for the Treatment of Ovarian Cancer Article Snippet: Subsequently, 1 × 10 6 OV-90 cells were resuspended in 40 μL of electroporation buffer (Miltenyi Biotec, Bergisch Gladbach, Germany), including 10 μL of ribonucleoprotein complexes (2.7 μg total), and transferred to an electroporation cuvette (Miltenyi Biotec, Bergisch Gladbach, Germany). .. Subsequently, 1 × 10 6 OV-90 cells were resuspended in 40 μL of Article Title: Identification and Characterization of Fully Human FOLR1-Targeting CAR T Cells for the Treatment of Ovarian Cancer. Article Snippet: Briefly, CRISPR-Cas9 gRNA targeting FOLR1 (sequence: CCTACCTATATAGATTCAACTGG) was combined with CRISPR-Cas9 crRNA in a 1:1 ratio, incubated for 5 min at 95 ◦C, then, allowed to cool at RT for 20 min to form the gRNA complex. .. Subsequently, 1 × 106 OV-90 cells were resuspended in 40 μL of Selection:Article Title: Impact of culture vessel materials on biomanufacturing of dendritic cell-based immunotherapies in closed systems. Article Snippet: .. The Elutra makes use of disposable tubing sets and sealed elutriation chambers, allowing fast selection of monocytes with high recovery rate.26,53,54 The |